Skip to main navigation
Go to Cumberland Pharmaceuticals, Inc. homepage
  • About Us
    • Profile & Mission
    • Our Strategy
    • Board of Directors
    • Management Team
    • Company History
  • Our Products
    • Commercial Products
    • Pipeline Products
    • International Partners
  • Investor Relations
    • Overview
    • Corporate Update
    • Corporate Governance
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Historic Price Lookup
      • Ownership Profile
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • Earnings Calls & Presentations
    • Investor FAQs
    • Press Releases
    • Contact Investor Relations
  • News
  • Cumberland Emerging Technologies
  • Blog
  • About Us
    • Profile & Mission
    • Our Strategy
    • Board of Directors
    • Management Team
    • Company History
  • Our Products
    • Commercial Products
    • Pipeline Products
    • International Partners
  • Investor Relations
    • Overview
    • Corporate Update
    • Corporate Governance
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Historic Price Lookup
      • Ownership Profile
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • Earnings Calls & Presentations
    • Investor FAQs
    • Press Releases
    • Contact Investor Relations
  • News
  • Cumberland Emerging Technologies
  • Blog
Contact
Contact

Press Releases

CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
May 28, 2026
PDF Version
Read More
CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
May 05, 2026
PDF Version
Read More
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
Apr 28, 2026
PDF Version
Read More
Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex
Apr 23, 2026
PDF Version
Read More
CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE
Apr 16, 2026
PDF Version
Read More
Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting
Mar 17, 2026
PDF Version
Read More
Cumberland Pharmaceuticals Reports 31% Fourth Quarter 2025 Revenue Growth
Mar 03, 2026
PDF Version
Read More
CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
Feb 25, 2026
PDF Version
Read More
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE
Feb 24, 2026
PDF Version
Read More
Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program
Feb 04, 2026
PDF Version
Read More
  • Current page 1
  • Page 2
  • Page 3
  • Next page ›
  • Last page »
Displaying 1 - 10 of 21

© 2026 Cumberland Pharmaceuticals, Inc. All Rights Reserved.

Privacy Policy
Accessibility Statement
Terms of Use